Dr Maurizio Vecchi evaluated the role of factor V Leiden, G1691A and G20210A prothrombin gene mutations.
The research team determined the occurrence of thrombosis in patients with inflammatory Bowel Disease (IBD).
The researchers enrolled 47 IBD patients, of which 30 had ulcerative colitis and 17 had Crohn's disease.
The patients had a positive history for thrombosis, occurring at arterial sites in 9 and venous sites at 38.
For each patient, 2 non-IBD subjects matched for sex and age, type, and site of thrombosis were used as controls.
The team amplified peripheral blood DNA specimens by PCR using appropriate primers and analyzed by restriction analysis on agarose gel electrophoresis.
Statistical analysis was performed by means of Fisher's exact test.
|1 or both mutations was lower in IBD patients with thrombosis than vs controls|
|American Journal of Gasroenterology|
The researchers found that the total number of subjects with 1 or both mutations was significantly lower in IBD patients with thrombosis than in control subjects.
The team noted that the total frequency of the mutated alleles was also significantly lower in IBD than in controls.
Prothrombotic mutations were particularly unfrequent in IBD patients with active disease at the time of thrombosis compared with patients with quiescent disease.
Dr Vecchi's team concludes, “The major inherited risk factors for thrombosis are significantly less frequent in thrombotic IBD patients than in thrombotic non-IBD subjects.”
“This suggests that acquired risk factors play the most relevant role in determining thromboembolic events observed in IBD patients, particularly during active phases of the disease.”